非小细胞肺癌患者CD8<sup>+</sup>CD56<sup>+</sup>NKT细胞亚群的特性研究-东南大学学报医学版

非小细胞肺癌患者CD8⁺CD56⁺NKT细胞亚群的特性研究

单位：1. 江苏大学医学院免疫学教研室, 江苏镇江 212013;
2. 江苏大学附属医院肿瘤研究院, 江苏镇江 212000

分类号：R392.9

出版年·卷·期（页码）：2019·38·第六期（1012-1018）

摘要：

目的：评估并探讨非小细胞肺癌（NSCLC）患者外周血中CD8⁺CD56⁺自然杀伤性T细胞（NKT细胞）的频数、功能特性和影响因素。方法：用流式细胞术分别检测47例NSCLC患者（肺癌组）及47例健康者（对照组）外周血CD8⁺CD56⁺NKT细胞频数及细胞表面CD57、Ki67、NKG2D、CD69分子的表达情况，并分析CD8⁺CD56⁺NKT细胞频数与患者临床病理特征的相关性。结果：肺癌组CD8⁺CD56⁺NKT细胞频数显著低于对照组（Z_NKT=2.083，P=0.037），细胞表面的CD57、NKG2D的表达率均低于对照组（Z_CD57=2.522，P=0.012；Z_NKG2D=2.121，P=0.034），CD69的表达率高于对照组（Z_CD69=2.159，P=0.031），差异均有统计学意义，两组Ki67分子的表达率无显著性差异（Z_Ki67=0.174，P=0.862）。不同性别、年龄（以60岁为界）、病理类型（鳞癌和腺癌）、TNM分期（Ⅰ~Ⅱ期、Ⅲ期、Ⅳ期）、治疗方案（初诊、化疗、靶向治疗、化疗联合靶向治疗）的NSCLC患者CD8⁺CD56⁺NKT细胞频数差异均无统计学意义（均P > 0.05）。结论：NSCLC患者外周血CD8⁺CD56⁺NKT细胞频数降低，尽管处于活化状态的细胞增多，但其细胞毒性减弱，功能耗竭，此外，CD8⁺CD56⁺NKT细胞频数不受性别、年龄、病理类型及TNM分期、治疗方案等因素的影响。

Objective: To investigate the frequency, biological characteristics and influence factors of peripheral blood CD8⁺CD56⁺NKT cells in patients with non-small cell lung cancer(NSCLC). Methods: Forty-seven NSCLC patients(NSCLC group) and 47 healthy people(control group) were recruited in this study. The frequency of CD8⁺CD56⁺ NKT cells and their expression rate of CD57、Ki67、NKG2D、CD69 in two groups were analyzed by four-color flow cytometry. Then the relationship between the frequency of CD8⁺CD56⁺ natural killer T cells(NKT cells) and the clinical characteristics of NSCLC patients were analyzed. Results: The frequency of CD8⁺CD56⁺NKT cells in peripheral blood of NSCLC group was significantly lower than that of the control group(Z_NKT=2.083,P=0.037). The expressing rate of CD57 and NKG2D on NKT cells were significantly reduced(Z_CD57=2.522,P=0.012;Z_NKG2D=2.121,P=0.034), in contrast, the expression rate of CD69 was significantly higher than that of the control group(Z_CD69=2.159, P=0.031), while the difference in Ki67 between the two groups was not statistically significant(Z_Ki67=0.174, P=0.862). Different gender, age(≤ 60 years old, >60 years old), pathological type(squamous cell carcinoma, adenocarcinoma), TNM stages(stage Ⅰ-Ⅱ、stage Ⅲ、stageⅣ)and treatment schemes(first visit, chemotherapy, targeted therapy, and chemotherapy combined with targeted therapy) did not affect the frequency of CD8⁺CD56⁺NKT cells in NSCLC patients, the difference was not statistically significant(P > 0.05). Conclusion: The frequency of peripheral blood CD8⁺CD56⁺NKT cells in NSCLC patients is decreased, while the proportion of the activated cells is increased, with weakened toxicity and exhaustion. The frequency CD8⁺CD56⁺NKT cells is not affected by gender, age, pathological type, TNM stages and treatment schemes.

参考文献：

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] LUCY G M,NICOLE C,CLIONA O F,et al.Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection[J].J Virol,2007,81(17):9292-9298.
[3] YANAGIHARA Y,SHIOZAWA K,TAKAI M,et al.Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA)[J].Clin Exp Immunol,2010,118(1):131-136.
[4] KORECK A,SURÖNYI A,SZÖNY B J,et al.CD3⁺CD56⁺ NK T cells are significantly decreased in the peripheral blood of patients with psoriasis[J].Clin Exp Immunol,2010,127(1):176-182.
[5] METELITSA L S.Anti-tumor potential of type-Ⅰ NKT cells against CD1d-positive and CD1d-negative tumors in humans[J].Clin Immunol,2011,140(2):119-129.
[6] LUTGENDORF S K,SOOD A K,BARRIE A,et al.Social support,psychological distress,and natural killer cell activity in ovarian cancer[J].J Clin Oncol,2005,23(28):7105-7113.
[7] SANDRA L V,MILUSH J M,SUCHITRA P,et al.CD57 defines a functionally distinct population of mature NK cells in the human CD56^dimCD16⁺ NK-cell subset[J].Blood,2010,116(19):3865-3874.
[8] TALEBIAN L,FISHER DA,WU J,et al.The natural killer-activating receptor,NKG2D,on CD3⁺CD8⁺T cells plays a critical role in identifying and killing autologous myeloma cells.[J] Transfusion,2014,54(6):1515-1521.
[9] 李清华,魏丽,王克强.CD69分子在γδΤ细胞中的应用进展[J].中华生物医学工程杂志,2016,22(4):337-339.
[10] ELENA A,MASAKI T,HALDER R C,et al.Cross-regulation between type Ⅰ and type Ⅱ NKT cells in regulating tumor immunity:a new immunoregulatory axis[J].J Immunol,2007,179(8):5126-5136.
[11] BERZOFSKY J T M.The contrasting roles of NKT cells in tumor immunity[J].Curr Mol Med,2009,9(6):667-672.
[12] PYSZNIAK M,RYBOJAD P,POGODA K,et al.Percentages of NKT cells in the tissues of patients with non-small cell lung cancer who underwent surgical treatment[J].Kardiochir Torakochirurgia Pol,2014,1:34-39.
[13] JANE K R,LAURA M E,TONY O C,et al.Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro[J].Hum Immunol,2006,67(11):863-873.
[14] KOBAYASHI T,DOFF B L,REARDEN R C,et al.NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma[J].Oncoimmunology,2015,4(3):e990793.
[15] MOLLING J W, KÖLGEN W,VAN DER VLIET H J,et al.Peripheral blood IFN-γ-secreting Vα24⁺Vβ11⁺ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load[J].Int J Cancer,2005,116(1):87-93.
[16] GULUBOVA M,MANOLOVA I,KYURKCHIEV D,et al.Decrease in intrahepatic CD56⁺ lymphocytes in gastric and colorectal cancer patients with liver metastases[J].Apmis,2010,117(12):870-879.
[17] ZDRAZILOVA-DUBSKA L,VALIK D,BUDINSKA E,et al. NKT-like cells are expanded in solid tumour patients[J].Klin Onkol,2012,25 Suppl 2:21-25.
[18] PAN K,WANG Q J,LIU Q,et al.The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer[J].Tumor Biol,2014,35(1):701-707.
[19] MOLLING J W,LANGIUS J A,LANGENDIJK J A,et al.Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma[J].J Clin Oncol,2007,25(7):862-868.
[20] JOEL C,HAOYU S,WELLING T H,et al.T cell anergy,exhaustion,senescence,and stemness in the tumor microenvironment[J].Curr Opin Immunol,2013,25(2):214-221.
[21] KARED H,MARTELLI S,NG T P,et al.CD57 in human natural killer cells and T-lymphocytes[J].Cancer Immunol Immunother,2016,65(4):441-452.
[22] SONG Y,WANG B,SONG R,et al.T-cell Immunoglobulin and ITIM Domain Contributes to CD8+T-cell Immunosenescence[J].Aging Cell,2018,17(2):e12716.
[23] MARTIN B,PAESMANS M,MASCAUX C,et al.Ki-67 expression and patients survival in lung cancer:systematic review of the literature with meta-analysis[J].Br J Cancer,2004,91(12):2018-2025.
[24] 臧怡雯,周易明.NKG2D及其配体在肿瘤免疫中的研究进展[J].复旦学报(医学版),2011,38(4):367-371.
[25] ZHOU X,ZHANG P,LUO W,et al.Ketamine induces apoptosis in lung adenocarcinoma cells by regulating the expression of CD69[J].Cancer Med,2018,7(3):788-795.
[26] LE V D H,VANDENBERGHE P.Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors:evidence for systemic activation of the T cell compartment[J].Leuk Res,1998,22(2):175-184.
[27] ZUMWALT T J,MILDRED A,AJAY G,et al.Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB⁺ CD8⁺ T-cell infiltration[J].Oncotarget,2015,6(5):2981-2991.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录